CryoPort, Inc.
20382 Barents Sea Circle
Lake Forest
California
92630
United States
Tel: 949-470-2300
Fax: 949-470-2306
Website: http://www.cryoport.com/
Email: contact@cryoport.com
269 articles about CryoPort, Inc.
-
Cryoport Reports Fourth Quarter and Full Year 2023 Financial Results
3/12/2024
Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for cell & gene therapies, today announced financial results for the fourth quarter (Q4) and year (FY) ended December 31, 2023.
-
Cryoport to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
2/27/2024
Cryoport, Inc. today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2023 on Tuesday, March 12, 2024 after U.S. markets close.
-
Cryoport to Report Third Quarter 2023 Financial Results on November 8, 2023
10/25/2023
Cryoport, Inc. today announced that the Company will report financial results for the third quarter ended September 30, 2023 on Wednesday, November 8, 2023 after U.S. markets close.
-
Cryoport Inks New Multi-Year Supply Chain Solutions Agreement with Monash IVF
10/12/2023
Cryoport, Inc. announced that the Company has signed a new three-year supply chain solutions agreement with Monash IVF Group Limited, a leading provider of assisted reproductive services, as well as specialist women's imaging and diagnostic services in Australia and Southeast Asia.
-
Cryoport and Cell and Gene Therapy Catapult Announce Strategic Collaboration at Stevenage Manufacturing Innovation Centre for Advancement of Cell and Gene Therapies
10/10/2023
Cryoport, Inc. and the Cell and Gene Therapy Catapult ("CGT Catapult"), an independent innovation and technology organisation specializing in the advancement of cell and gene therapies, today announced the organisations have entered into a new strategic partnership to support the advancement of cell and gene therapies.
-
Cryoport Reports Second Quarter 2023 Financial Results
8/9/2023
Cryoport, Inc. announced financial results for the second quarter and first half of 2023.
-
Cryoport to Report Second Quarter 2023 Financial Results on August 9, 2023
8/2/2023
Cryoport, Inc. today announced that the Company will report financial results for the second quarter ended June 30, 2023 on Wednesday, August 9, 2023 after U.S. markets close.
-
Cryoport Announces Certain Preliminary Results for Second Quarter & Updates 2023 Revenue Expectations
7/12/2023
Cryoport, Inc., a leading global provider of innovative products and services for the fast growing cell and gene therapy industry, announced certain preliminary results for second quarter 2023 and updated its expectations for full year 2023 revenue expectations.
-
Cryoport Reports First Quarter 2023 Results
5/4/2023
Cryoport, Inc., a leading global provider of innovative temperature-controlled supply chain solutions for the life sciences, announced financial results for the three months ended March 31, 2023.
-
Cryoport to Report First Quarter 2023 Financial Results on May 4, 2023
4/27/2023
Cryoport, Inc. today announced that the Company will report financial results for the first quarter ended March 31, 2023.
-
Cryoport Signs New Supply Chain Solutions Agreement with Boston IVF to Support Reproductive Material Shipments Across the U.S.
4/25/2023
Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company") today announced that it has signed a new three-year agreement with Boston IVF, a pioneer in reproductive healthcare and innovative research and one of the world's most experienced fertility treatment providers.
-
Cryoport Announces Multi-Year Agreement with Inception Fertility
3/28/2023
Cryoport, Inc., a leading global provider of innovative temperature-controlled supply chain solutions for the life sciences industry and a leader in supply chain solutions for the reproductive medicine markets, announced a multi-year agreement with Inception Fertility™, North America's largest provider of comprehensive fertility services.
-
Cryoport Confirms No Financial Exposure to Silicon Valley Bank
3/13/2023
Cryoport, Inc., a leading global provider of innovative temperature-controlled supply chain solutions for the life sciences industry, with focus on the bio-pharmaceutical and cell and gene therapy markets, confirms that the Company does not have any exposure or business relationship with Silicon Valley Bank.
-
Cryoport Reports Fourth Quarter and Full Year 2022 Results
2/23/2023
Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions for the life sciences industry, with focus on the bio-pharmaceutical and cell and gene therapy markets, today announced financial results for the three months and year ended December 31, 2022.
-
Cryoport to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
2/15/2023
Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company") today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2022 on Thursday, February 23, 2023 after U.S. markets close.
-
Cryoport Announces New Strategic Partnership with Syneos Health to Advance Cell & Gene Therapies
1/18/2023
Cryoport, Inc. today announced a new strategic partnership with Syneos Health® (NASDAQ: SYNH), the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success.
-
Cryoport to Present at the J.P. Morgan 41st Annual Healthcare Conference
12/20/2022
Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that Jerrell Shelton, the Company's Chief Executive Officer, will be presenting at the J.P. Morgan 41st Annual Healthcare conference, taking place from January 9 - 12, 2023 in San Francisco, CA.
-
Cryoport Reports Results for the Third Quarter 2022
11/3/2022
Cryoport, Inc., a global leader in temperature-controlled supply chain solutions for the life sciences industry, announced financial results for the three- and nine-month periods ended September 30, 2022.
-
Cryoport to Report Third Quarter 2022 Financial Results on November 3, 2022
10/27/2022
Cryoport, Inc. today announced that the Company will report financial results for the three months period ended September 30, 2022 (third quarter 2022) on Thursday, November 3, 2022.
-
Cryoport Enters into Strategic Relationship with Takeda's BioLife Plasma Services
9/8/2022
Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced it has entered into a strategic relationship with BioLife Plasma Services, part of the global biopharmaceutical company Takeda.